telaprevir + raltegravir

This agent is a **combination of telaprevir, a hepatitis C virus (HCV) protease inhibitor, and raltegravir, an HIV-1 integrase strand transfer inhibitor**. Telaprevir inhibits the NS3/4A protease, an enzyme essential for HCV replication, while raltegravir prevents the integration of HIV-1 DNA into the cellular genome by inhibiting the integrase enzyme. The rationale behind this combination is to treat patients co-infected with HIV and HCV by targeting both viruses with direct-acting antivirals. There is no evidence this specific combination has a unique brand or code name; it is used as a regimen in special cases of co-infection.

Brand names

IncivekIsentress

Other names

Treatment sequence BA-Tibotec BVBA-hepatitis C-HIV infectionTreatment sequence BATreatment sequence ABtelaprevir/raltegravir